A phase I trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION&#174; peptide-drug conjugate delivering sustained tumor microenvironment (TME) release of exatecan in patients with FAP-positive solid tumors

AVA-6103 - Avacta

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_2/print/presentation/9248

Alexander I. Spira; Nehal J. Lakhani; Judy S. Wang; Muhammad R. Khawaja; Ruairidh Edwards; Karen Campbell; Curtis Rink; Christiana Nikolova; David Liebowitz

Jul 17, 2026